Multidisciplinary scientist working on multi-omics approaches to understand and overcome drug resistance in Multiple Myeloma.
Multiple myeloma (MM) is a cancer of plasma cells, accounting for 2% of cancers, responsible for 3000 deaths every year in the UK alone. MM is incurable and has a poor prognosis, with a five-year survival rate of 47%. Multiple treatment strategies are employed for MM patients, including proteasome inhibitors, immunomodulatory drugs and corticosteroids. Although these drug treatments are effective at MM cell killing, patients eventually become refractory and resistant to further treatment. Anti-cancer drug resistance is one of the biggest limitations in treatment of MM. Therefore it is imperative to understand the mechanisms involved in the development of the resistant phenotype, and to find compounds that could potentially reverse this phenotype and to make patients treatment-sensitive again.
Drug resistance is extremely complex, and has been shown to involve numerous changes in the genome, transcriptome, proteome and epigeome. Therefore multi-omics techniques must be employed to fully capture the multiple layers driving the differences between drug-resistant and drug-sensitive states.
I have employed a variety of multi-omics techniques, such as bulk and single cell RNA-seq, ATAC-seq, CyTOF and LC-MS/MS proteomics.
I obtained my BSc in Natural Sciences (Biomedical Sciences and Mathematics & Statistics) from University College London, with First Class Honours. I completed a summer studentship in the Department of Physiology, Anatomy and Genetics at Oxford, funded by the British Heart Foundation, and that motivated me to apply to the University of Oxford Doctoral Training Centre (DTC) for a DPhil in Systems Approaches to Biomedical Sciences.
Currently I am working in NDORMS as part of the Oppermann Group, researching proteasome inhibitor resistance in Multiple Myeloma. I have been trained as both a wet-lab scientist and bioinformatician, generating my own experimental data for computational analysis.
I am funded by the Engineering and Physical Sciences Research Council (EPSRC) and GlaxoSmithKline (GSK).
In my spare time I enjoy all things sports, including: rowing and coxing for St Hilda's College Boat Club, competing in sport karate, playing lacrosse and playing/watching football.